$13.660
+0.122 (+0.89%)Al cierre
Comparativa sectorial de AGMB
In the context of the broader market, AGMB competes directly with industry leaders such as CRMD and VSTM. With a market capitalization of $672.73M, it holds a significant position in the sector. When comparing efficiency, AGMB's gross margin of N/A stands against CRMD's 75.66% and VSTM's 89.92%. Such benchmarking helps identify whether Agomab Therapeutics NV is trading at a premium or discount relative to its financial performance.
Desempeño financiero de Agomab Therapeutics NV
Agomab has a negative EPS of -0.71 for Q3 2024 and a forward P/E ratio of 0, indicating it is not yet profitable but is investing in future growth through clinical trials.
Financials
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.